What is the appropriate cefuroxime (Zinnat) dosing regimen for an adult with chronic kidney disease stage 5 (eGFR < 15 mL/min/1.73 m²), including adjustments for intermittent hemodialysis?

Cefuroxime (Zinnat) Dosing in CKD Stage 5

For an adult with CKD stage 5 (eGFR <15 mL/min/1.73 m²) not on dialysis, administer cefuroxime 250-500 mg every 48 hours; for patients on intermittent hemodialysis, give 250-500 mg after each dialysis session.

Dosing Algorithm Based on Renal Function

The pharmacokinetic data clearly demonstrates that cefuroxime elimination is directly dependent on kidney function, requiring substantial dose adjustments in severe renal impairment 1.

For CKD Stage 5 (eGFR <15 mL/min) NOT on Dialysis:

• Standard individual dose: Every 48 hours 1
• The elimination half-life extends dramatically from 1.4 hours in normal renal function to 16.8-22.3 hours in severe renal impairment 1, 2
• Volume of distribution remains stable at approximately 0.82 L/kg, but can increase to 29.6 L in the most severe cases 2

For Patients on Intermittent Hemodialysis:

• Give supplemental dose after each dialysis session
• Cefuroxime is removed by hemodialysis, necessitating post-dialysis dosing
• The standard dose (250-500 mg depending on infection severity) should be administered after dialysis is completed

Key Pharmacokinetic Considerations

The relationship between renal function and cefuroxime elimination follows a predictable linear pattern 1:

• Elimination rate constant (kel) can be calculated: kel (h⁻¹) = 0.0046 × Clcr + 0.0108
• Both systemic clearance and renal clearance decrease linearly with declining creatinine clearance
• Extrarenal clearance is minimal at 8.24 mL/min 2

Clinical Efficacy and Safety

Despite the prolonged half-life in severe renal impairment, appropriately dose-adjusted cefuroxime maintains clinical efficacy 2:

• Symptoms of infection resolved within 3-4 days in patients with severe renal dysfunction
• No nephrotoxicity was observed, even with concomitant furosemide use
• The drug was well-tolerated without significant adverse effects

Critical Pitfalls to Avoid

1. Do not use standard dosing intervals - The 16.8-22.3 hour half-life in CKD stage 5 means standard 8-12 hour dosing will cause dangerous accumulation 1, 2

2. Do not forget post-dialysis supplementation - Hemodialysis removes cefuroxime, requiring replacement dosing after each session

3. Monitor for accumulation - Even with appropriate dose adjustments, therapeutic drug monitoring may be warranted in patients with fluctuating renal function or those requiring prolonged therapy

4. Adjust for infection severity - While the interval changes, the individual dose (250-500 mg) should still reflect the severity and site of infection

---

Note: The FDA drug label evidence provided 3 pertains to a topical miconazole/zinc oxide product for diaper dermatitis, not cefuroxime (Zinnat), and was therefore not used in this recommendation.